Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases : vimarsana.com

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies...

Related Keywords

California , United States , Colorado , Germany , Emeryville , Denver , Bochum , Nordrhein Westfalen , American , Peter Maag , Lily Sarafan , Jeffrey Dunn , Marinos Dalakas , University Hospital , Nasdaq , National Institutes Of Health , American Academy Of Neurology , Exchange Commission , Thomas Jefferson University Hospitals , Prnewswire Kyverna Therapeutics Inc , Kyverna Therapeutics Inc , Department Of Neurology , American Academy , Jeremias Motte , Neurological Sciences , Stanford University , Palo Alto , Multiple Sclerosis , Northern European , Myasthenia Gravis , National Institutes , Annual Report , Quarterly Reports , Media Contact , Nature Medicine , Kyverna Therapeutics , Pharmaceuticals , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Trade Show News , Clinical Trials Amp Medical Discoveries ,